Clinical trials: Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS)
Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS), Myelodysplastic Syndromes (MDS)
Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation
This study will enroll participants with myelodysplastic syndromes (MDS) with an Isocitrate dehydrogenase protein, 1 (IDH1) mutation, who have not received treatment with a hypomethylating agent previously.
- Trial name
- PyramIDH (NCT06465953)
- Testing
- Ivosidenib, Azacitidine
- Where
- 62 sites in United States, Australia and 8 more
- Volunteers
- 48 people
- Sponsor
- Institut de Recherches Internationales Servier